Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age19+
SponsorSamsung Medical Center
About this trial
SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown. This prospective, single-center, open-label randomized controlled trial evaluates whether an SGLT2 inhibitor started after successful electrical cardioversion reduces recurrence of atrial tachyarrhythmia at 1 month in patients with persistent atrial fibrillation and heart failure with preserved ejection fraction. 200 patients will be randomized 1:1 to receive an SGLT2 inhibitor or no SGLT2 inhibitor.
Eligibility criteria
Qualifiers
Age ≥19 years
Persistent atrial fibrillation
H2FPEF score ≥6 or HFA-PEFF score ≥5
Restoration of sinus rhythm after electrical cardioversion
Disqualifiers
Previous use of an SGLT2 inhibitor
Intracardiac thrombus on transesophageal echocardiography
Refusal to participate
Trial design
Treatments tested in this trial
- SGLT2 inhibitors (Dapagliflozin and Empagliflozin)
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov